Joseph Terracina
Dermatology · Greenville, MSNPI 1316909724
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,606 of the $86,421 with a category attached, or 71.3%. AbbVie accounts for 96.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $28,107 and has fallen 63.4% since, to $10,274 in 2025. Among dermatology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 414 payments — averaging $208.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$83K
- Johnson & Johnson$1K
- Lilly USA, LLC$762
- UCB, Inc.$346
- Incyte Corporation$225
- Pfizer$189
- plus $529 from 12 others
What the payments were for
- Consulting fees$4881%
- Speaking & faculty fees$61,60671%
- Travel & lodging$16,80819%
- Food & beverage$7,2898%
- Education$2310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 234 | $83,012 |
| Johnson & Johnson | 67 | $1,360 |
| Lilly USA, LLC | 39 | $762 |
| UCB, Inc. | 20 | $346 |
| Incyte Corporation | 14 | $225 |
| Pfizer | 13 | $189 |
| LEO Pharma Inc. | 7 | $117 |
| Novartis | 6 | $94 |
| Janssen Scientific Affairs, LLC | 1 | $93 |
| Regeneron Healthcare Solutions, Inc. | 4 | $76 |
| Amgen | 2 | $34 |
| Boehringer Ingelheim | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Journey Medical Corporation | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,421 in reported general payments places this provider in the 90th percentile of 78 dermatology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 29 | $625,706 |
| RinvoqUpadacitinib | 53 | $342,465 |
| Humira(Cf) PenAdalimumab | 27 | $261,258 |
| SkyriziRisankizumab-Rzaa | 11 | $236,863 |
| Enbrel SureclickEtanercept | 21 | $158,056 |
| OpzeluraRuxolitinib Phosphate | 21 | $42,592 |
| Betamethasone Dipropionate | 177 | $13,906 |
| Clobetasol Propionate | 233 | $9,082 |
| Ketoconazole | 599 | $8,908 |
| Hydroxychloroquine Sulfate | 229 | $5,925 |
| Pimecrolimus | 19 | $4,098 |
| Triamcinolone Acetonide | 304 | $3,603 |
| Minocycline Hcl | 134 | $3,373 |
| Aripiprazole | 102 | $3,316 |
| Cefdinir | 284 | $3,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Skyrizi | $83,012 | $579,32864 claims |
| Incyte CorporationOpzelura | $225 | $42,59221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 78 dermatology providers in Mississippi.
Other dermatology in Greenville
- Jeremy JacksonJackson$450K
- Lindsey ZubritskyOcean Springs$349K
- Maureen OffiahHattiesburg$275K
- Lyndsay ShippOxford$246K
- Steven ShapiroHattiesburg$165K
- Thy HuynhJackson$51K
- Patrick BolerClinton$44K
- Jeffrey HouinTupelo$27K
- Robert BrodellJackson$26K
- Amanda DaggettRidgeland$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.